Abstract | PURPOSE OF REVIEW: The recent decade has been a 'golden age' for antifungal therapy. The introduction of a novel class of antifungals, the echinocandins, has revolutionized the therapy for invasive candidiasis, provided increasing options for antifungal prophylaxis in high-risk patients and energized the debate regarding combination antifungal therapy for invasive mycoses. RECENT FINDINGS: SUMMARY: The echinocandins as a class offer an advance in the treatment of invasive candidiasis, an additional option for prophylaxis and an attractive choice for the study of combination antifungal therapy. Particularly for the major indication (treatment of invasive candidiasis), major clinical differences between agents have not been noted.
|
Authors | Aimee K Zaas |
Journal | Current opinion in infectious diseases
(Curr Opin Infect Dis)
Vol. 21
Issue 4
Pg. 426-32
(Aug 2008)
ISSN: 1473-6527 [Electronic] United States |
PMID | 18594297
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antifungal Agents
- Echinocandins
- Triazoles
|
Topics |
- Antifungal Agents
(pharmacology, therapeutic use)
- Aspergillosis
(drug therapy)
- Candidiasis
(drug therapy, prevention & control)
- Chemoprevention
- Drug Therapy, Combination
- Echinocandins
(pharmacology, therapeutic use)
- Fungi
(drug effects)
- Humans
- Triazoles
(therapeutic use)
|